Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
- PMID: 29529307
- DOI: 10.1093/rheumatology/key023
Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Abstract
Objectives: This analysis set out to estimate the risk of opportunistic infection (OI) among patients with RA by biologic class.
Methods: The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis is a prospective observational cohort study established to evaluate safety of biologic therapies. The population included adults commencing biologic therapy for RA. The primary outcome was any serious OI excluding tuberculosis (TB). Event rates were compared across biologic classes using Cox proportional hazards with adjustment for potential confounders identified a priori. Analysis of the incidence of TB was performed separately.
Results: In total, 19 282 patients with 106 347 years of follow-up were studied; 142 non-TB OI were identified at a rate of 134 cases/100 000 patient years (pyrs). The overall incidence of OI was not significantly different between the different drug classes; however, the rate of Pneumocystis infection was significantly higher with rituximab than with anti-TNF therapy (adjusted hazard ratio = 3.2, 95% CI: 1.4, 7.5). The rate of TB fell dramatically over the study period (783 cases/100 000 pyrs in 2002 to 38 cases/100 000 pyrs in 2015). The incidence of TB was significantly lower among rituximab users than anti-TNF users, with 12 cases/100 000 pyrs compared with 65 cases/100 000 pyrs.
Conclusions: The overall rate of OI was not significantly different between drug classes; however, a subtle difference in the pattern of OI was seen between the cohorts. Patient factors such as age, gender and comorbidity were the most important predictors of OI.
Similar articles
-
Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Ann Rheum Dis. 2018 Jun;77(6):905-910. doi: 10.1136/annrheumdis-2017-212825. Epub 2018 Mar 28. Ann Rheum Dis. 2018. PMID: 29592917
-
Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register.Rheumatology (Oxford). 2018 Apr 1;57(4):651-655. doi: 10.1093/rheumatology/kex469. Rheumatology (Oxford). 2018. PMID: 29340619
-
Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Arthritis Rheumatol. 2021 Oct;73(10):1800-1809. doi: 10.1002/art.41754. Epub 2021 Aug 17. Arthritis Rheumatol. 2021. PMID: 33844458
-
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.Autoimmun Rev. 2015 Jun;14(6):503-9. doi: 10.1016/j.autrev.2015.01.011. Epub 2015 Jan 21. Autoimmun Rev. 2015. PMID: 25617816 Review.
-
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.Ann Rheum Dis. 2015 Dec;74(12):2107-16. doi: 10.1136/annrheumdis-2015-207841. Epub 2015 Sep 22. Ann Rheum Dis. 2015. PMID: 26395500 Review.
Cited by
-
Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region.Pharmaceutics. 2022 Oct 28;14(11):2328. doi: 10.3390/pharmaceutics14112328. Pharmaceutics. 2022. PMID: 36365146 Free PMC article.
-
Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study.Arthritis Res Ther. 2022 Jun 10;24(1):136. doi: 10.1186/s13075-022-02821-x. Arthritis Res Ther. 2022. PMID: 35689239 Free PMC article. Clinical Trial.
-
The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review.J Clin Med. 2021 Feb 1;10(3):509. doi: 10.3390/jcm10030509. J Clin Med. 2021. PMID: 33535498 Free PMC article. Review.
-
Biological therapy safety in chronic inflammatory arthropathy patients.Eur J Rheumatol. 2020 Apr;7(2):53-59. doi: 10.5152/eurjrheum.2019.19123. Epub 2020 Jan 2. Eur J Rheumatol. 2020. PMID: 32644925 Free PMC article.
-
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.Clin Pharmacol Ther. 2019 Apr;105(4):1031-1039. doi: 10.1002/cpt.1276. Epub 2018 Dec 4. Clin Pharmacol Ther. 2019. PMID: 30402880 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical